Annotation Detail

Information
Associated Genes
ERBB2
Associated Variants
ERBB2 AMPLIFICATION ( ENST00000269571.10 )
ERBB2 AMPLIFICATION ( ENST00000269571.10 )
Associated Disease
colorectal cancer
Source Database
CIViC Evidence
Description
In update report of a phase 2 trial, Patients with colorectal cancer with HER2 amplification received pertuzumab and trastuzumab. Objective response rate was 32% (n=18/57).
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/7302
Gene URL
https://civic.genome.wustl.edu/links/genes/20
Variant URL
https://civic.genome.wustl.edu/links/variants/306
Rating
3
Evidence Type
Predictive
Disease
Colorectal Cancer
Evidence Direction
Supports
Drug
Pertuzumab,Trastuzumab
Evidence Level
B
Clinical Significance
Sensitivity/Response
Pubmed
30857956
Drugs
Drug NameSensitivitySupported
PertuzumabSensitivitytrue
TrastuzumabSensitivitytrue